Ultragenyx Pharmaceutical Inc’s filing revealed that its Chief Financial Officer Horn Howard unloaded Company’s shares for reported $72114.0 on Mar 06 ’25. In the deal valued at $40.40 per share,1,785 shares were sold. As a result of this transaction, Horn Howard now holds 106,169 shares worth roughly $3.41 million.
Then, Kassberg Thomas Richard sold 6,028 shares, generating $253,779 in total proceeds. Upon selling the shares at $42.10, the CBO & EVP now owns 265,238 shares.
Before that, Parschauer Karah Herdman sold 12,846 shares. Ultragenyx Pharmaceutical Inc shares valued at $540,817 were divested by the EVP and Chief Legal Officer at a price of $42.10 per share. As a result of the transaction, Parschauer Karah Herdman now holds 75,287 shares, worth roughly $2.42 million.
Goldman upgraded its Ultragenyx Pharmaceutical Inc [RARE] rating to a Buy from a a Neutral in a research note published on June 06, 2024; the price target was increased to $67 from $56. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late April with a ‘”an Outperform”‘ rating. Wells Fargo began covering RARE with “an Overweight” recommendation on December 08, 2023.
Price Performance Review of RARE
On Monday, Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] saw its stock fall -0.89% to $32.14. Over the last five days, the stock has lost -11.24%. Ultragenyx Pharmaceutical Inc shares have fallen nearly -23.60% since the year began. Nevertheless, the stocks have fallen -31.73% over the past one year. While a 52-week high of $60.37 was reached on 02/06/25, a 52-week low of $32.07 was recorded on 04/07/25. SMA at 50 days reached $40.63, while 200 days put it at $46.90.
Levels Of Support And Resistance For RARE Stock
The 24-hour chart illustrates a support level at 30.62, which if violated will result in even more drops to 29.09. On the upside, there is a resistance level at 33.51. A further resistance level may holdings at 34.87. The Relative Strength Index (RSI) on the 14-day chart is 28.11, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.60, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.76%. Stochastics %K at 15.21% indicates the stock is a buying.
How much short interest is there in Ultragenyx Pharmaceutical Inc?
A steep rise in short interest was recorded in Ultragenyx Pharmaceutical Inc stocks on 2025-03-14, growing by 0.53 million shares to a total of 4.81 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 4.28 million shares. There was a rise of 11.0%, which implies that there is a positive sentiment for the stock.
